Main Article Content
Objective: To check out the prescription trend for the hepatitis C i.e. to analyze the combination therapy. The association
of therapy plan with the age of the patient was also studied.
Material and Methods: Prescriptions were collected from 97 patients diagnosed with hepatitis C from December 2016
to February 2017. Statistical calculations were carried out on these prescriptions to analyze the trend and to see the
association of therapy plan with the age of the patient.
Results: In the prescription trend the combination of ribavirin 1200mg/day (400mg TID) and sofosbuver 400mg/day
was found to be the most frequent. Second frequent therapy was the combination of oral therapeutic agent (ribavirin
1200mg/day (400mg TID)) and an injectable (Peginterferonalfa 2a) whereas interferon alfa 2a were also used along
with the ribavirin. There was no association found between age of the patient and the therapy plan.
Conclusion: Oral therapy for the hepatitis C treatment is the most frequent therapy plan in the Jinnah hospital where
as the second frequent therapy plan was a combination of oral and the injectable. On the other hand there is no association
of age of patient with the therapy plan followed for hepatitis C.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
CopyRight . © 2008-2018 Khyber Medical College Peshawar | All Rights Reserved